Point of Care Molecular Diagnostics Market - Global Forecast 2025-2032

The point of care molecular diagnostics market is rapidly evolving, driven by urgent demand for rapid, reliable, and decentralized testing to support timely clinical decisions across diverse healthcare environments.

Market Snapshot: Point of Care Molecular Diagnostics

The Point of Care Molecular Diagnostics Market grew from USD 5.26 billion in 2024 to USD 5.64 billion in 2025. It is expected to continue growing at a CAGR of 7.61%, reaching USD 9.47 billion by 2032. This growth highlights expanding adoption among healthcare providers seeking streamlined, near-patient diagnostic capabilities for infectious diseases, genetic testing, and oncology, alongside increasing technological integration. The market is shifting towards advanced software and intelligent platforms, supporting data-driven care and efficient health system operations.

Scope & Segmentation

• Product Types: Instruments, reagents & kits, and software solutions power real-time molecular analysis and robust data management.
• Technologies: Includes genetic sequencing-based, hybridization-based, isothermal nucleic acid amplification technology (INAAT), microarray-based, and PCR-based methodologies, enabling a range of rapid testing platforms.
• Applications: Cardiology, genetic testing (carrier screening, newborn screening, prenatal testing), infectious disease (gastrointestinal, respiratory, sexually transmitted, tropical), and oncology (liquid biopsy, mutation profiling, oncogene panels).
• End Users: Clinics, diagnostic laboratories, home care settings, and hospitals deploy point of care molecular diagnostics for decentralized and integrated care pathways.
• Geographies: Coverage includes Americas (North America, Latin America), Europe, Middle East & Africa, and Asia-Pacific—with granular insight across key countries such as the United States, Canada, Brazil, United Kingdom, Germany, China, Japan, Australia, and others.
• Companies Profiled: Notable players include Abbott Laboratories, Becton, Dickinson and Company, ACON LABS INC., Binx Health, bioMérieux SA, Cardinal Health, Chembio Diagnostics, Co-Diagnostics, Danaher Corporation, DiaSorin, EKF Diagnostics Holdings, FHoffmann-La Roche AG, Genomadix, Henry Schein, Meridian Bioscience, Novartis AG, OraSure Technologies, Pfizer, QIAGEN, Quidel Corporation, SD Biosensor, Sekisui Diagnostics, SHUWEN BIOTECH, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, among others.

Key Takeaways for Senior Decision-Makers

• Portable and benchtop solutions now deliver near-laboratory quality diagnostics directly at the patient interface, reducing the turnaround from sample to action.
• Integration of software and cloud-based analytics enables remote monitoring, proactive patient management, and seamless workflow integration with electronic health records.
• Segment-specific innovation addresses cardiology, genetic testing, infectious disease, and oncology applications, supporting more precise and rapid clinical pathways.
• Decentralized testing is expanding beyond hospitals, with adoption in clinics, home care, and remote settings driving patient-centric models.
• Regional adoption dynamics vary, with North America advancing emergency preparedness, Europe focusing on value-based care, and Asia-Pacific leveraging manufacturing capacities for cost and scale efficiencies.
• Strategic collaboration across manufacturers, reagent suppliers, and technology startups enables market leaders to continuously evolve diagnostic offerings and maintain a competitive edge.

Tariff Impact on Industry Dynamics

Recent tariff schedule adjustments in 2025 have altered cost structures for point of care molecular diagnostics, impacting both manufacturers and healthcare providers. Import duties on instruments, reagents, and software have prompted a reevaluation of procurement strategies, driving increased sourcing from alternative geographies and adaptation of pricing models. Regulatory requirements for documentation and customs clearance intensified, with companies focusing on local partnerships and production to maintain product availability and supply resilience.

Methodology & Data Sources

This analysis is based on a rigorous research framework combining secondary source review, primary expert interviews with executives and laboratory directors, and systematic multi-layer validation. Data triangulation with press releases, trade associations, and company disclosures supports accuracy. Additional quality assurance included peer review and updates regarding geopolitical and tariff considerations.

Why This Report Matters

• Senior executives and decision-makers gain actionable insights for strategic planning, procurement optimization, and investment in point of care molecular diagnostics.
• Comprehensive segmentation and regional coverage help organizations identify growth opportunities tailored to specific clinical applications and geographic markets.
• The report’s forward-looking analysis supports technology selection, partnership strategies, and navigation of regulatory and trade policy shifts.

Conclusion

Point of care molecular diagnostics is accelerating the shift toward decentralized and data-driven healthcare delivery. Organizations aligning innovation with clinical and operational needs will sustain growth and realize meaningful impact across the care continuum.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.